More on KTTA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (9/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Pasithea Therapeutics (NQ:KTTA)
Delayed: 0.47 +0.02 (4.44%)
Prev. Close $0.45  
Open$0.48 
52 Wk High$ 
52 Wk Low$ 
Day High$0.52 
Day Low$0.47 
P/E N/A  
EPS$ 
Volume888,579 

Friends, Peers and Foes (?): KTTAW (more...)

Jul 8, 2026 07:02 AM Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Jul 8, 2026 07:02 AM Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Jul 1, 2026 08:02 PM Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Coastlands Capital LP
Jun 30, 2026 07:00 AM Pasithea reports Phase 1 interim data for cancer drug PAS-004
Jun 30, 2026 07:00 AM Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus
Jun 23, 2026 05:41 PM Form SCHEDULE 13G Pasithea Therapeutics Filed by: Stonepine Capital Management, LLC
Jun 22, 2026 10:31 AM Form 4 Pasithea Therapeutics For: Jun 17 Filed by: Coastlands Capital LP
Jun 16, 2026 07:00 AM PASITHEA amends NF1 trial protocol, adds higher doses and longer treatment
Jun 16, 2026 07:00 AM Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Jun 15, 2026 07:02 AM Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
View All Articles

Entities mentioned with KTTA

View All Entities